Muhamad Syahrul Fitri Zawawi

Dr. Muhamad Syahrul Fitri Zawawi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
ADA.A.S.S.K. Dharmapatni
A.A.S.S.K. Dharmapatni
MCM. D. Cantley
M. D. Cantley
KMK.P. McHugh
K.P. McHugh
DHD.R. Haynes
D.R. Haynes
TCTania Crotti
Tania Crotti

25 March 2015 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
EPEgon Perilli
Egon Perilli
RSR. L. Stansborough
R. L. Stansborough
VMV. Marino
V. Marino
MCMelissa D. Cantley
Melissa D. Cantley
TCTania Crotti
Tania Crotti

22 April 2015 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
VMVictor Marino
Victor Marino
EPEgon Perilli
Egon Perilli
MCMelissa D. Cantley
Melissa D. Cantley
Jiake XuJiake Xu
Jiake Xu
TCTania Crotti
Tania Crotti

13 June 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FAFarah Alwani Binti Azaman
Farah Alwani Binti Azaman
MFMargaret E. Brennan Fournet
Margaret E. Brennan Fournet
SHSuzina Sheikh Ab Hamid
Suzina Sheikh Ab Hamid
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
VJValdemiro Amaro da Silva Júnior
Valdemiro Amaro da Silva Júnior
Declan M. DevineDeclan M. Devine
Declan M. Devine
The field of bone tissue engineering has shown a great variety of bone graft substitute materials under development to date, with the aim to reconstruct new bone tissue while maintaining characteristics close to the native bone. Currently, insufficient scaffold degradation remains the critical limitation for the success of tailoring the bone formation turnover rate. This study examines novel scaffold formulations to improve the degradation rate in vivo, utilising chitosan (CS), hydroxyapatite (HAp) and fluorapatite (FAp) at different ratios. Previously, the P28 peptide was reported to present similar, if not better performance in new bone production to its native protein, bone morphogenetic protein-2 (BMP-2), in promoting osteogenesis in vivo. Therefore, various P28 concentrations were incorporated into the CS/HAp/FAp scaffolds for implantation in vivo. H&E staining shows minimal scaffold traces in most of the defects induced after eight weeks, showing the enhanced biodegradability of the scaffolds in vivo. The HE stain highlighted the thickened periosteum indicating a new bone formation in the scaffolds, where CS/HAp/FAp/P28 75 µg and CS/HAp/FAp/P28 150 µg showed the cortical and trabecular thickening. CS/HAp/FAp 1:1 P28 150 µg scaffolds showed a higher intensity of calcein green label with the absence of xylenol orange label, which indicates that mineralisation and remodelling was not ongoing four days prior to sacrifice. Conversely, double labelling was observed in the CS/HAp/FAp 1:1 P28 25 µg and CS/HAp/FAp/P28 75 µg, which indicates continued mineralisation at days ten and four prior to sacrifice. Based on the HE and fluorochrome label, CS/HAp/FAp 1:1 with P28 peptides presented a consistent positive osteoinduction following the implantation in the femoral condyle defects. These results show the ability of this tailored formulation to improve the scaffold degradation for bone regeneration and present a cost-effective alternative to BMP-2.

Verified
Journal Article
Open access
PDF file
NHNur Shukriyah Mohamad Hazir
Nur Shukriyah Mohamad Hazir
NYNor Hamdan Mohamad Yahaya
Nor Hamdan Mohamad Yahaya
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
HDHanafi Damanhuri
Hanafi Damanhuri
NMNorazlina Mohamed
Norazlina Mohamed
EAEkram Alias
Ekram Alias
Changes in mitochondrial bioenergetics are believed to take place during osteoclastogenesis. This study aims to assess changes in mitochondrial bioenergetics and reactive oxygen species (ROS) levels during polyethylene (PE)-induced osteoclastogenesis in vitro. For this purpose, RAW264.7 cells were cultured for nine days and allowed to differentiate into osteoclasts in the presence of PE and RANKL. The total TRAP-positive cells, resorption activity, expression of osteoclast marker genes, ROS level, mitochondrial bioenergetics, glycolysis, and substrate utilization were measured. The effect of tocotrienols-rich fraction (TRF) treatment (50 ng/mL) on those parameters during PE-induced osteoclastogenesis was also studied. During PE-induced osteoclastogenesis, as depicted by an increase in TRAP-positive cells and gene expression of osteoclast-related markers, higher proton leak, higher extracellular acidification rate (ECAR), as well as higher levels of ROS and NADPH oxidases (NOXs) were observed in the differentiated cells. The oxidation level of some substrates in the differentiated group was higher than in other groups. TRF treatment significantly reduced the number of TRAP-positive osteoclasts, bone resorption activity, and ROS levels, as well as modulating the gene expression of antioxidant-related genes and mitochondrial function. In conclusion, changes in mitochondrial bioenergetics and substrate utilization were observed during PE-induced osteoclastogenesis, while TRF treatment modulated these changes.

1 March 2021 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
HCHui Heng Chua
Hui Heng Chua
SSSharifah Emilia Tuan Sharif
Sharifah Emilia Tuan Sharif
WIWan Faisham Nu’man Wan Ismail
Wan Faisham Nu’man Wan Ismail
MZMuhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
SASARIMAH ABDULLAH
SARIMAH ABDULLAH
Background: The receptor activator of nuclear factor kappa B ligand (RANKL) is one of the key regulators of bone remodelling in bone oncology, including osteosarcoma. We assessed RANKL immunohistochemical expression in osteosarcoma, its association, and disease-free survival with the patients’ clinicopathological characteristics. Methods: One hundred osteosarcoma cases from 2003 to 2018 in Hospital Universiti Sains Malaysia were retrieved. The tissue samples were stained for RANKL, and the association with the clinicopathological characteristics was evaluated. Staining was interpreted in a semiquantitative scoring system and classified into negative and positive expressions. Results: Eighty-two cases had a positive expression of RANKL in which 56 and 26 patients were classified as low expression and high expression, respectively. The positive expression of RANKL did not show a significant association with clinicopathological characteristics. However, Kaplan Meier survival analysis showed a significant improvement in the disease-free survival patients who underwent limb salvage surgery (LSS) than amputated patients (p-value 0.002), whereas poorer survival was observed among conventional osteosarcomas compared to non-conventional osteosarcoma (p-value 0.01). Conclusion: Limb salvage surgery had proven to improve osteosarcoma patients’ survival compared to amputation, which could improve overall quality of life in osteosarcoma patients. However, our data did not show a significant association between positive RANKL immunohistochemistry with any of the clinicopathological characteristics and patients’ final survival. Further studies may be acquired to understand the suitability of using RANKL immunohistochemistry as prognostication in the management of osteosarcoma patients.